Article Sidebar

Submitted
14 August 2017
Accepted
14 August 2017
Published
14 August 2017
Download
PDF
Statistic
Read Counter : 754 Download : 818

Main Article Content

Abstract

Glucocorticoid is widely used in medical treatment as an immune system or an inflammation therapy. However its long term administration can cause life-threatening side effects. One of them is bone mass loss which increases the risk of bone fractures in the long-term use. Bone lining cells derived from mesenchymal stem cells, which serve as a backup cell bone-forming osteoblasts. Glucocorticoids acting directly on osteoblasts, bone lining cells when reduced due to increased apoptosis, the reserve cells to bone formation will be decreased. The aim of this study was to count the amount of apoptotic bone lining cells after long term glucocorticoid administration. This study used Rattus norvegicus females aged 3 months that were divided into 3 groups, each group consisted of 7 rats. The groups are: (1) control group; (2) treatment group 1 were given glucocorticoid 0.01 mg/day; (3) treatment group 2 were given glucocorticoid 0.2mg/day. The treatment carried out for 4 weeks and at the end of treatment, rats were sacrified and continued with preparation, and the number of bone lining cells that undergoing apoptosis was calculated through examination of the femur bone tissue metaphysis section using immunohistochemical technique. All data were analyzed with statistical analysis Anova. The result showed that the number of apoptotic bone lining cells increased in group with glucocorticoid administration 0.01 mg/day and 0.2 mg/day compared to control group with p = 0.000 (p <0.05). The number of apoptotic bone lining cells on the group of glucocorticoid dose 0.2 mg/day higher than the group of glucocorticoid dose 0.01 mg/day with p = 0.000 (p <0.05). In conclusion, long term glucocorticoid administration increase apoptosis of bone lining cells.

Keywords

Bone lining cells apoptosis glucocorticoid

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Sari, G. M. (2017). THE EFFECT OF LONG TERM ADMINISTRATION OF GLUCOCORTICOID TO BONE LINING CELLS APOPTOSIS. Folia Medica Indonesiana, 52(4), 251–257. https://doi.org/10.20473/fmi.v52i4.5471
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE (2000). The localization of the functional glucocorticoid receptor alpha in human bone. J Clin Endocrinol Metab 85, 883-889
  2. Adler RA and Hochberg MC (2003). Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163, 2619-2624
  3. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman J, Reginster JY, Rozenberg S (2011). Loading and skeletal development and maintenance. Journal of Osteoporosis 2011, 1-16
  4. Bonewald LF (2011). The amazing osteocyte. J Bone Miner Res 26, 229-238
  5. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS (2008). The cell biology of bone metabolism. J Clin Pathol 61, 577-587
  6. Downey PA and Siegel MI (2006). Bone biology and the clinical implications for osteoporosis. Phys Ther 86, 77-91
  7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997). A transcriptional activator of osteoblast differentiation. Cell 89, 747-754
  8. Dvorak J, Feddermann N, Grimm K (2006). Glucocorticosteroids in football: use and misuse. Br J Sports Med 40, 148-154
  9. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA (2008). Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149, 146-153
  10. Ganong WF (2005). Review of Medical Physiology, New York, McGraw-Hill Comp, p 342-380
  11. Garcí­a AJ and Reyes CD (2005). Bio-adhesive surfaces to promote osteoblast differentiation and bone formation. J Dent Res 84, 407-413
  12. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES (2002). Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277, 13430-13437
  13. Hall JE and Guyton AC (2011). Guyton and Hall Textbook of Medical Physiology, Philadelphia, Saunders/Elsevier
  14. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999). Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389
  15. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS (2006). Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592-5599
  16. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL (2006). Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116, 2152-2160
  17. Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S (2013). Mechanosensation and transduction in osteocytes. Bone 54, 182-190
  18. Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M (2005). Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 280, 30192-30200
  19. Kumar V, Abbas AK, Fausto N (2005). Robbins and Cotran Pathologic Basic of Disease, 7th ed, Philadelphia, Elsevier, p 26-106
  20. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF (2006). Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21, 466-476
  21. Lorenzo J, Horowitz M, Choi Y (2008). Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29, 403-440
  22. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003). Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83, 965-1016
  23. Lu NZ, Collins JB, Grissom SF, Cidlowski JA (2007). Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol 27, 7143-7160
  24. Manolagas SC (2000). Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21, 115-137
  25. Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res 57, 385-409
  26. McNamara LM (2010). Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7, 353-372
  27. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003). Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144, 5441-5449
  28. Owen GR, Meredith DO, ap Gwynn I, Richards RG (2005). Focal adhesion quantification - a new assay of material biocompatibility? Review. Eur Cell Mater 9, 85-96
  29. Park SY, Avraham HK, Avraham S (2004). RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 279, 33315-33322
  30. Plotkin LI, Manolagas SC, Bellido T (2007). Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem 282, 24120-24130
  31. Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T (2005). Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol 289, C633-C643
  32. Raison CL and Miller AH (2003). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160, 1554–1565
  33. Raisz LG (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115, 3318-3325
  34. Riggs BL1, Khosla S, Melton LJ 3rd (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23, 279-302
  35. Seibel MJ (2005). Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26, 97-122
  36. Sherwood L (2010). Human Physiology: From Cells to Systems, 7th ed, Belmont, Brooks/Cole, Cengage Learning, p 769
  37. Suatmadji DW (2001). Pathogenesis of steroid-induced osteoporosis. Naskah lengkap Simposium Asma & Osteoporosis, PDPI Cabang Malang/RSUD Dr Saiful Anwar, p 41-55
  38. Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006). Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147, 3613-3622
  39. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003). Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278, 44667-44674
  40. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000). Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478-3484
  41. Watts NB (1999). Clinical utility of biochemical markers of bone remodeling. Clin Chem 45, 1359-1368
  42. Weinstein RS1, Nicholas RW, Manolagas SC (2000). Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85, 2907-2912